$3.67
3.97% yesterday
Nasdaq, May 20, 10:02 pm CET
ISIN
US25056L1035
Symbol
DSGN

Design Therapeutics Inc Stock price

$3.67
+0.08 2.23% 1M
-1.81 33.03% 6M
-2.50 40.52% YTD
-0.73 16.59% 1Y
-7.73 67.81% 3Y
-16.33 81.65% 5Y
-16.33 81.65% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.14 3.97%
ISIN
US25056L1035
Symbol
DSGN
Sector
Industry

Key metrics

Market capitalization $208.34m
Enterprise Value $-19.19m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.40
P/B ratio (TTM) P/B ratio 0.91
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-68.40m
Free Cash Flow (TTM) Free Cash Flow $-47.67m
Cash position $229.67m
EPS (TTM) EPS $-0.99
Short interest 9.45%
Show more

Is Design Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Design Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Design Therapeutics Inc forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Design Therapeutics Inc forecast:

Buy
33%
Hold
67%

Financial data from Design Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.61 0.61
9% 9%
-
-0.61 -0.61
9% 9%
-
- Selling and Administrative Expenses 18 18
7% 7%
-
- Research and Development Expense 49 49
2% 2%
-
-68 -68
4% 4%
-
- Depreciation and Amortization 0.61 0.61
9% 9%
-
EBIT (Operating Income) EBIT -68 -68
4% 4%
-
Net Profit -56 -56
4% 4%
-

In millions USD.

Don't miss a Thing! We will send you all news about Design Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Design Therapeutics Inc Stock News

Neutral
GlobeNewsWire
8 days ago
CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York.
Neutral
GlobeNewsWire
13 days ago
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy  (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations Through up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Thera...
Neutral
GlobeNewsWire
20 days ago
Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025
More Design Therapeutics Inc News

Company Profile

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded on December 18, 2017 by Pratik Shah and Aseem Z. Ansari and is headquartered in Carlsbad, CA.

Head office United States
CEO Pratik Shah
Employees 54
Founded 2017
Website www.designtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today